Prostate cancer is one of the most commonly diagnosed cancers, where accurate biomarker assessment is critical for effective diagnosis* and treatment. At OptraSCAN, we harness advanced digital pathology tools, including digital slide scanners, to provide precise and reliable insights through our Prostate Cancer Biomarker Analysis. Our innovative digital pathology solutions empower pathologists and researchers with objective and data-driven information in cancer management.
OptraSCAN’s Prostate Cancer Biomarker Analysis Algorithm is a cutting-edge digital pathology solution designed to automate the evaluation of key biomarkers, including a deep learning-based approach to Gleason grading. This automated Gleason grading tool applies advanced AI to H&E-stained digital slides, ensuring objective and reproducible grading of prostate cancer tissue, crucial for accurate prognostication and treatment planning.
Leveraging deep learning, the algorithm analyzes high-resolution H&E-stained images using digital histopathology,, providing consistent and objective Gleason grades to enhance prognostic accuracy.
The algorithm enables precise analysis of biomarkers relevant to prostate cancer, offering critical insights into tumor aggressiveness and potential response to treatment.
Automated evaluation reduces the time and variability associated with manual Gleason grading, delivering reproducible results with reduced workflow burdens.
Includes an integrated reporting feature for streamlined case management, facilitating organized documentation and efficient access to insights.
High-resolution whole-slide imaging is used to acquire, capturing cellular details for comprehensive biomarker and Gleason grade analysis.
The images undergo preprocessing to ensure optimal quality for analysis, followed by an automated check for region adequacy.
The algorithm performs Gleason grading, recognizing patterns in tumor architecture and cell morphology, to accurately classify prostate tissue samples.
The algorithm generates detailed scores, grades, and biomarker analysis reports, supporting pathologists in making informed decisions quickly.
By applying AI for cancer diagnostics* for consistent Gleason grading and biomarker analysis, the algorithm improves reliability and precision in prostate cancer diagnosis*.
Automated analysis speeds up prostate cancer evaluations, reducing turnaround time and enabling pathologists to focus on high-level clinical decisions.
The algorithm minimizes variability, ensuring reliable Gleason grading and biomarker assessment across different cases.
The effectiveness of our Cervical Cancer Analysis Algorithm is supported by rigorous research and clinical validation in 9 hospitals across 10,000 patients as certified by DBT. Utilizing cloud-based digital pathology workflows, we collaborate with leading institutions and experts in the field to ensure our solutions meet the highest standards of accuracy and reliability. Our virtual pathology platforms for telemedicine makes commitment to continuous improvement by refining our algorithms based on the latest scientific findings and clinical feedback to facilitate remote diagnostics* and support rural labs with remote pathology systems, resulting in our algorithm being recognized and awarded by the Government of India.
OptraSCAN’s Prostate Cancer Biomarker Analysis Algorithm is rigorously validated through collaborations with leading institutions and experts. This ongoing research ensures our algorithm meets the highest standards in accuracy, consistency, and clinical applicability, with continuous improvements based on the latest scientific findings and clinical insights.
OptraSCAN’s Prostate Cancer Biomarker Analysis Algorithm is at the forefront of digital pathology, offering an innovative approach to prostate cancer diagnosis* and management. By integrating AI-driven solutions with automated Gleason grading, we provide pathologists with powerful tools to advance prostate cancer care.
For more information about our Prostate Cancer Biomarker Analysis Algorithm or to schedule a demonstration, please contact us at info@optrascan.com. Join us in transforming prostate cancer diagnostics* through technology and innovation!
